Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 2
1981 1
1982 2
1983 3
1984 2
1985 3
1986 5
1987 5
1988 6
1989 9
1990 5
1991 7
1992 4
1993 8
1994 5
1995 9
1996 8
1997 4
1998 6
1999 7
2000 11
2001 8
2002 9
2003 7
2004 7
2005 5
2006 4
2007 5
2008 1
2009 3
2010 3
2011 9
2012 4
2013 5
2014 4
2015 5
2016 8
2017 5
2018 1
2019 3
2020 2
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

205 results
Results by year
Filters applied: . Clear all
Page 1
Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.
Perera TPS, Jovcheva E, Mevellec L, Vialard J, De Lange D, Verhulst T, Paulussen C, Van De Ven K, King P, Freyne E, Rees DC, Squires M, Saxty G, Page M, Murray CW, Gilissen R, Ward G, Thompson NT, Newell DR, Cheng N, Xie L, Yang J, Platero SJ, Karkera JD, Moy C, Angibaud P, Laquerre S, Lorenzi MV. Perera TPS, et al. Among authors: newell dr. Mol Cancer Ther. 2017 Jun;16(6):1010-1020. doi: 10.1158/1535-7163.MCT-16-0589. Epub 2017 Mar 24. Mol Cancer Ther. 2017. PMID: 28341788 Free article.
2-Arylamino-6-ethynylpurines are cysteine-targeting irreversible inhibitors of Nek2 kinase.
Matheson CJ, Coxon CR, Bayliss R, Boxall K, Carbain B, Fry AM, Hardcastle IR, Harnor SJ, Mas-Droux C, Newell DR, Richards MW, Sivaprakasam M, Turner D, Griffin RJ, Golding BT, Cano C. Matheson CJ, et al. Among authors: newell dr. RSC Med Chem. 2020 May 22;11(6):707-731. doi: 10.1039/d0md00074d. eCollection 2020 Jun 1. RSC Med Chem. 2020. PMID: 33479670 Free PMC article.
Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy.
Willoughby CE, Jiang Y, Thomas HD, Willmore E, Kyle S, Wittner A, Phillips N, Zhao Y, Tudhope SJ, Prendergast L, Junge G, Lourenco LM, Finlay MRV, Turner P, Munck JM, Griffin RJ, Rennison T, Pickles J, Cano C, Newell DR, Reeves HL, Ryan AJ, Wedge SR. Willoughby CE, et al. Among authors: newell dr. J Clin Invest. 2020 Jan 2;130(1):258-271. doi: 10.1172/JCI127483. J Clin Invest. 2020. PMID: 31581151 Free PMC article.
Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38Ī± and BRD4.
Myers SM, Miller DC, Molyneux L, Arasta M, Bawn RH, Blackburn TJ, Cook SJ, Edwards N, Endicott JA, Golding BT, Griffin RJ, Hammonds T, Hardcastle IR, Harnor SJ, Heptinstall AB, Lochhead PA, Martin MP, Martin NC, Newell DR, Owen PJ, Pang LC, Reuillon T, Rigoreau LJM, Thomas HD, Tucker JA, Wang LZ, Wong AC, Noble MEM, Wedge SR, Cano C. Myers SM, et al. Among authors: newell dr. Eur J Med Chem. 2019 Sep 15;178:530-543. doi: 10.1016/j.ejmech.2019.05.057. Epub 2019 May 25. Eur J Med Chem. 2019. PMID: 31212132
Structure-guided design of purine-based probes for selective Nek2 inhibition.
Coxon CR, Wong C, Bayliss R, Boxall K, Carr KH, Fry AM, Hardcastle IR, Matheson CJ, Newell DR, Sivaprakasam M, Thomas H, Turner D, Yeoh S, Wang LZ, Griffin RJ, Golding BT, Cano C. Coxon CR, et al. Among authors: newell dr. Oncotarget. 2017 Mar 21;8(12):19089-19124. doi: 10.18632/oncotarget.13249. Oncotarget. 2017. PMID: 27833088 Free PMC article.
Identification and Characterization of an Irreversible Inhibitor of CDK2.
Anscombe E, Meschini E, Mora-Vidal R, Martin MP, Staunton D, Geitmann M, Danielson UH, Stanley WA, Wang LZ, Reuillon T, Golding BT, Cano C, Newell DR, Noble ME, Wedge SR, Endicott JA, Griffin RJ. Anscombe E, et al. Among authors: newell dr. Chem Biol. 2015 Sep 17;22(9):1159-64. doi: 10.1016/j.chembiol.2015.07.018. Epub 2015 Aug 27. Chem Biol. 2015. PMID: 26320860 Free PMC article.
205 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page